JOHN FARMER to Clinical Trials as Topic
This is a "connection" page, showing publications JOHN FARMER has written about Clinical Trials as Topic.
Connection Strength
0.815
-
Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep. 2008 Feb; 8(1):71-7.
Score: 0.202
-
Optimal low-density lipoprotein levels: evidence from epidemiology and clinical trials. Curr Atheroscler Rep. 2006 Mar; 8(2):157-62.
Score: 0.177
-
Coronary heart disease: clinical trials review. Curr Atheroscler Rep. 2000 May; 2(3):189-93.
Score: 0.118
-
Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Atheroscler Rep. 2007 Aug; 9(2):162-8.
Score: 0.049
-
Rationale for aggressive lipid lowering: evidence from clinical trials. Expert Rev Cardiovasc Ther. 2004 May; 2(3):305-9.
Score: 0.039
-
The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol. 2003 Jul 03; 92(1A):3i-9i.
Score: 0.037
-
Statins and myotoxicity. Curr Atheroscler Rep. 2003 Mar; 5(2):96-100.
Score: 0.036
-
Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002 Sep 24; 106(13):1595-8.
Score: 0.035
-
Learning from the cerivastatin experience. Lancet. 2001 Oct 27; 358(9291):1383-5.
Score: 0.033
-
Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol. 1998 Sep 24; 82(6A):26M-31M.
Score: 0.026
-
Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis. 1998 Sep-Oct; 41(2):71-94.
Score: 0.026
-
Current and future therapeutic approaches to hyperlipidemia. Adv Pharmacol. 1996; 35:79-114.
Score: 0.022
-
The role of inflammation in the pathogenesis of heart failure. Curr Cardiol Rep. 2002 May; 4(3):200-5.
Score: 0.008
-
Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 1997 Dec; 8(6):354-61.
Score: 0.006